Meningococcal vaccines. Global epidemiological situation and strategies for prevention by vaccination;Vacunas antimeningocócicas. Situación epidemiológica mundial y estrategias de prevención mediante la vacunación

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 33, Issue 4, 2015, Pages 257-267

  Rivero Calle, Irene ^a   Rodriguez Tenreiro Sánchez, Carmen ^a   Martinón Torres, Federico ^a  

^a Santiago University Clinical Hospital   (Spain)

Author keywords

Antimeningococcal vaccines; Meningococcal disease; Neisseria meningitides

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL COLONIZATION; CHEMOPROPHYLAXIS; CHILDHOOD DISEASE; EPIDEMIC; HUMAN; IMMUNIZATION; MENINGOCOCCOSIS; VACCINATION; ANTIBIOTIC PROPHYLAXIS; CHILD HEALTH CARE; DISEASE CARRIER; ENDEMIC DISEASE; EPIDEMIC MENINGITIS; INFECTION PREVENTION; MENINGITIS; MENINGOCOCCEMIA; MORTALITY; NASOPHARYNX; NEISSERIA MENINGITIDIS; PUBLIC HEALTH SERVICE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CLASSIFICATION; DISEASE OUTBREAKS; EUROPE; GLOBAL HEALTH; HETEROZYGOTE; INCIDENCE; INFANT; ISOLATION AND PURIFICATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; SEROTYPING; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC PROPHYLAXIS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DISEASE RESERVOIRS; EUROPE; GLOBAL HEALTH; HUMANS; INCIDENCE; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NASOPHARYNX; NEISSERIA MENINGITIDIS; SEROTYPING; VACCINATION; YOUNG ADULT;

EID: 84926253491     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2015.03.001     Document Type: Article

References (49)

1. Centro Nacional de Epidemiologia. Instituto de Salud Carlos III. Red Nacional de Vigilancia Epidemiológica. Protocolos de enfermedades de declaración obligatoria. Madrid, 2013.
2. National Institute for Health and Clinical Excellence. Bacterial meningitis and meningococcal septicaemia. Management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. NICE clinical guideline 102. National Collaborating Centre for Women's and Children's Health, 2010. Disponible en: http://www.nice.org.uk/nicemedia/live/13027/49339/49339.pdf
3. M. Apicella Neisseria meningitidis G. Mandell, J. Bennett, R. Dolin, Enfermedades infecciosas. Principios y práctica. 7 a ed. 2012 Elsevier España Barcelona 2742 2757
4. D. Panatto, D. Amicizia, P.L. Lai, and R. Gasparini Neisseria meningitidis B vaccines Expert Rev Vaccines. 10 2011 1337 1351
5. K. Thorburn, P. Baines, A. Thomson, and C.A. Hart Mortality in severe meningococcal disease Arch Dis Child. 85 2001 382 385
6. F. Moraga, and F. Martinon-Torres La enfermedad meningocócica: pasado, presente y futuro. 2013 Editorial Graficos Montseny Girona
7. European Centre for Disease Prevention and Control. Annual epidemiological report Reporting on 2011 surveillance data and 2012 epidemic intelligence data. 2013. Disponible en: http://www.ecdc.europa.eu/en/publications/publications/annual-epidemiological-report-2012.pdf
8. S.A. Halperin, J.A. Bettinger, B. Greenwood, L.H. Harrison, J. Jelfs, and S.N. Ladhani The changing and dynamic epidemiology of meningococcal disease Vaccine. 2011
9. A. Salas, L. Fachal, S. Marcos-Alonso, A. Vega, F. Martinón-Torres Grupo de investigación ESIGEM (Estudio Sobre la Influencia Genética en la Enfermedad Meningocócica) Investigating the role of mitochondrial haplogroups in genetic predisposition to meningococcal disease PLoS One. 4 2009 e8347 10.1371/journal.pone.0008347
10. European Centre for Disease Prevention and Control. Disponible en: http://www.ecdc.europa.eu/en/data-tools/Pages/home.aspx
11. Servicio de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Comentario epidemiológico de las enfermedades de declaración obligatoria y sistema de información microbiológica. España. 2012 Boletín epidemiológico semanal. 21 2013 143 160
12. D.A. Caugant, G. Tzanakaki, and P. Kriz Lessons from meningococcal carriage studies FEMS Microbiol Rev 31 2007 52 63
13. M.C.J. Maiden, and D.A. Caugant The population biology of Neisseria meningitidis: implications for meningococcal disease, epidemiology and control M. Frosch, M.C.J. Maiden, Handbook of meningococcal disease. 2006 Wiley-VCH Verlag GmbH & Co. KGaA Weinheim, Germany 17 35
14. J. Suart Public health management M. Frosch, M.C.J. Maiden, Handbook of meningococcal disease. 2006 Wiley-VCH Verlag GmbH & Co. KGaA Weinheim, Germany 519 531
15. J.S. Bennett, D.T. Griffiths, N.D. McCarthy, K.L. Sleeman, K.A. Jolley, and D.W. Crook Genetic Diversity and Carriage Dynamics of Neisseria lactamica in Infants Infect Immun 73 2005 2424 2432
16. World Health Organization. Meningococcal meningitis. Fact sheet 141. November 2012. Updated February 2015, Disponible en: http://www.who.int/mediacentre/factsheets/fs141/en/index.html
17. M. Montero-Martin, D. Inwald, E.D. Carrol, and F. Martinon-Torres Prognostic markers of meningococcal disease in children: recent advances and future challenges Expert Rev Anti Infect Ther. 12 2014 1357 1369
18. C. Schoen, J. Blom, H. Claus, A. Schramm- Gluck, P. Brandt, and T. Muller Whole- genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis Proc Natl Acad Sci U S A. 105 2008 3473 3478
19. S. Davila, V.J. Wright, C.C. Khor, K.S. Sim, A. Binder, W.B. Breunis, and F. Martinón-Torres International Meningococcal Genetics Consortium. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease Nat Genet. 42 2010 772 776
20. Fraser, A. et al. Antibiotics for preventing meningococcal infections. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004785.pub2.
21. J.M. Stuart, K.A. Cartwright, P.M. Robinson, and N.D. Noah Does eradication of meningococcal carriage in household contacts prevent secondary cases of meningococcal disease? BMJ 298 1989 569 570
22. L.K. Tan, G.M. Carlone, and R. Borrow Advances in the development of vaccines against Neisseria meningitidis N Engl J Med. 362 2010 1511 1520
23. E.C. Gotschlich, I. Goldschneider, and M.S. Artenstein Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state Journal of Experimental Medicine. 129 1969 1385 1395
24. E.C. Gotschlich, Teh Yung Liu, and S. Malcolm Artenstein. Human immunity to the meningococcus III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides Exp Med 129 1969 1349 1365
25. R. Gold, M.L. Lepow, and Goldschneider Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants J Clin Znvest. 59 1975 1536 1547
26. J.D. Farquhar, W.A. Hankins, A.N. Desanctis, J.L. Demeio, and D.P. Metzgar Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, and Y Proc Soc Exp Biol Med. 157 1978 79 82
27. W.A. Hankins, J.M. Gwaltney Jr.; J.O. Hendley, J.D. Farquhar, and J.S. Samuelson Clinical and serological evaluation of a Meningococcal Polysaccharide Vaccine Groups A, C, Y and W-135 Proc Soc Exper Biol Med. 169 1982 54 57
28. F.A. Wyle, M.S. Artenstein, B.L. Brandt, E.C. Tramont, D.L. Kasper, and P.L.ET-AL> Altier Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines J Infect Dis. 126 1972 514 522
29. D.M. Granoff Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease Pediatr Infect Dis J. 32 2013 372 373
30. R. Rappuoli, M. Pizza, S. Black, and E.R. Moxon Towards a meningitis-free world. Can we eliminate meningococcal meningitis? Vaccine. 30 Suppl 2 2012 B1 B106
31. F.A. Moraga Llop Novedades en vacunología 2010 M. Campins Martí, F.A. Moraga Llop, Vacunas 2011. 2012 Gráficas Campás Barcelona 189 198
32. C.J. Gill Novel assessment of a novel meningitis B vaccine Lancet Infect Dis. 13 2013 381 382
33. P.C. Richmond, H.S. Marshall, M.D. Nissen, Q. Jiang, K.U. Jansen, M. Garcés-Sánchez, F. Martinón-Torres, J. Beeslaar, L. Szenborn, J. Wysocki, J. Eiden, S.L. Harris, T.R. Jones, and J.L. Perez 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial Lancet Infect Dis. 12 2012 597 607
34. Meningococcal vaccines: WHO position paper. November 2011 Wkly Epidemiol Rec. 86 2011 521 539
35. S.B. Black, and S.A. Plotkin Meningococcal disease from the public health policy perspective Vac- cine. 30 Suppl2 2012 B37 B39
36. P. Kaaijk, A. van der Ende, G. Berbers, G.P. van den Dobbelsteen, and N.Y. Rots Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection?. Experience from the Netherlands BMC Infectious Diseases 12 2012 35
37. European Centre for Disease Prevention and Control. Euvac net. http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules/Pages/schedules.aspx
38. JCVI statement on the use of meningococcal vaccines in the routine childhood immunisation programme.January2012http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@ab/documents/digitalasset/dh-1324 43.pdf.
39. C. Rodríguez-Tenreiro, and F. Martinón-Torres Vacuna universal frente a meningococo B An Pediatr Contin. 9 2011 60 63
40. X. Bai, J. Findlow, and R. Borrow Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles Expert Opin Biol Ther. 11 2011 969 985
41. Nissen MD, Marshall HS, Richmond P, Lambert SB, Roberton D, Gruber WC, et al. A randomized, placebo controlled, double-blind, phase 1 trial of ascending doses of meningococcal group rLP2086 vaccine. En: Proceedings of the 26th annual meeting of the European Society for Paedriatric Infectious Diseases. 2008.
42. F. Martinon-Torres, F. Gimenez-Sanchez, E. Bernaola-Iturbe, J. Diez-Domingo, Q. Jiang, and J.L. Perez A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants Vaccine. 32 2014 5206 5211 doi: 10.1016/j.vaccine.2014.07.049. Epub 2014 Jul 29
43. R. Rappuoli Reverse vaccinology, a genome-based approach to vaccine development Vaccine. 19 2001 2688 2691
44. K.L. Seib, X. Zhao, and R. Rappuoli Developing vaccines in the era of genomics: A decade of reverse vaccinology Clin MicrobiolInfect. 18 Suppl 5 2012 109 116 60
45. Gil A, Barranco D, Batalla J, Bayas JM, Campins M, Gorrotxategi Gorrotxategi P, Lluch J, Martinón-Torres F, Mellado MJ, Moreno-Pérez D, Uriel B, Vázquez JA. [Prevention of serogroup B meningococcal disease using a four-component vaccine.] An Pediatr (Barc). 2013 Oct 9. pii: S1695-4033(13)00169-0. doi: 10.1016/j.anpedi.2013.04.013.
46. Agencia Europea de Medicamentos (Web). Bexsero: vacuna antimeningocoÍcica grupo B. Disponible: http://www.ema.europa.eu/docs/es-ES/document-library/EPAR-Product-Information/human/002333/WC500137881.pdf
47. Grupo de Trabajo "Uso de 4 CMenB en situaciones especiales", del Consejo Interterritorial del Sistema Nacional de Salud, Recomendaciones de utilización de la vacuna frente a enfermedad meningocócica por serogrupo B disponible en: http://www.sergas.es/gal/DocumentacionTecnica/docs/SaudePublica/meningococica/2-Recom-uso-4CMenB.pdf
48. F. Martinón-Torres Immunisation against meningococcus B: the case of Spain Lancet. 382 2013 1552 1553
49. A. Sarfatti, F. Martinón-Torres, and S. Nadel Vaccine evaluation: lessons from a meningococcal B vaccine Arch Dis Child. 2015 [Epub ahead of print]